Cuprior (trientine) was approved for the treatment of patients with Wilson’s disease by: The European Medical Agency (EMA), European Union, on September 5th, 20172 The EMA granted Orphan Drug Designation to Cuprior (trientine) previously2. Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.